MX2023012794A - Regímenes de dosificación expandidos para inhibidores de integrina. - Google Patents

Regímenes de dosificación expandidos para inhibidores de integrina.

Info

Publication number
MX2023012794A
MX2023012794A MX2023012794A MX2023012794A MX2023012794A MX 2023012794 A MX2023012794 A MX 2023012794A MX 2023012794 A MX2023012794 A MX 2023012794A MX 2023012794 A MX2023012794 A MX 2023012794A MX 2023012794 A MX2023012794 A MX 2023012794A
Authority
MX
Mexico
Prior art keywords
sup
formula
expanded
integrin inhibitors
dosing regimes
Prior art date
Application number
MX2023012794A
Other languages
English (en)
Spanish (es)
Inventor
Eric Lefebvre
Scott Turner
Martin Decaris
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Publication of MX2023012794A publication Critical patent/MX2023012794A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2023012794A 2021-04-30 2022-04-29 Regímenes de dosificación expandidos para inhibidores de integrina. MX2023012794A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163182757P 2021-04-30 2021-04-30
PCT/US2022/072013 WO2022232838A1 (en) 2021-04-30 2022-04-29 Expanded dosage regimens for integrin inhibitors

Publications (1)

Publication Number Publication Date
MX2023012794A true MX2023012794A (es) 2023-12-15

Family

ID=83848780

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012794A MX2023012794A (es) 2021-04-30 2022-04-29 Regímenes de dosificación expandidos para inhibidores de integrina.

Country Status (14)

Country Link
US (1) US20230028658A1 (https=)
EP (1) EP4329755A4 (https=)
JP (1) JP2024517765A (https=)
KR (1) KR20240024060A (https=)
CN (1) CN117615760A (https=)
AU (1) AU2022265730A1 (https=)
CA (1) CA3173787A1 (https=)
CL (1) CL2023003219A1 (https=)
CO (1) CO2023016295A2 (https=)
CR (1) CR20230553A (https=)
IL (1) IL308063A (https=)
MX (1) MX2023012794A (https=)
TW (1) TW202308637A (https=)
WO (1) WO2022232838A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN114173803A (zh) 2019-04-08 2022-03-11 普利安特治疗公司 氨基酸化合物的剂型和方案
EP4247472A4 (en) 2020-11-19 2024-10-09 Pliant Therapeutics, Inc. INTEGRIN INHIBITORS AND USES THEREOF
US20250197393A1 (en) 2023-12-14 2025-06-19 Pliant Therapeutics, Inc. Integrin inhibitor and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2984394T3 (es) * 2016-11-08 2024-10-29 Bristol Myers Squibb Co Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v
WO2019118938A1 (en) * 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
FI3761980T3 (fi) * 2018-03-07 2024-02-21 Pliant Therapeutics Inc Aminohappoyhdisteitä ja käyttömenetelmiä
CN114173803A (zh) * 2019-04-08 2022-03-11 普利安特治疗公司 氨基酸化合物的剂型和方案
CN115989235A (zh) * 2020-05-07 2023-04-18 普利安特治疗公司 使用氨基酸化合物治疗呼吸系统疾病的方法
TW202329973A (zh) * 2021-10-14 2023-08-01 美商普萊恩醫療公司 整合素抑制劑及其與其他藥劑併用之用途

Also Published As

Publication number Publication date
EP4329755A4 (en) 2025-03-19
CL2023003219A1 (es) 2024-05-31
IL308063A (en) 2023-12-01
TW202308637A (zh) 2023-03-01
CA3173787A1 (en) 2022-11-03
CN117615760A (zh) 2024-02-27
WO2022232838A1 (en) 2022-11-03
CR20230553A (es) 2024-04-01
US20230028658A1 (en) 2023-01-26
JP2024517765A (ja) 2024-04-23
EP4329755A1 (en) 2024-03-06
KR20240024060A (ko) 2024-02-23
CO2023016295A2 (es) 2023-12-11
AU2022265730A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
MX2023012794A (es) Regímenes de dosificación expandidos para inhibidores de integrina.
EP4509512A3 (en) Amino acid compounds and methods of use
MX2020014086A (es) Compuestos de aminoácidos con ligadores no ramificados y métodos de uso.
MX2021004015A (es) Compuestos de aminoacidos y metodos de uso.
MX2023007192A (es) Inhibidores de prmt5.
ZA202209563B (en) Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors
MX2024004438A (es) Inhibidores de integrinas y usos de los mismos en combinacion con otros agentes.
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
PH12020550698A1 (en) 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
EA201390723A1 (ru) Аминозамещенные производные бисфенилпентановой кислоты в качестве ингибиторов nep
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
PH12022550338A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
EA201391018A1 (ru) Препараты иммуносупрессантов
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
UA98757C2 (ru) Бензамидные соединения, полезные как ингибиторы деацетилазы гистонов
WO2024155965A3 (en) Biomarkers for use in integrin inhibitor therapy
JOP20240171A1 (ar) مركبات يوراسيل بها استبدال بـ n3 على هيئة مثبطات trpa1
DK1858861T3 (da) HIV-inhiberende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidiner
GEAP202416376A (en) Tetrahydrothieno pyridine derivatives as ddrs inhibitors
EA202092110A1 (ru) Аминокислотные соединения и способы применения
GEAP202516640A (en) Crystal form of a pde4 inhibitor
WO2025019626A3 (en) Proteosome complex inhibitors targeting clpp1p2 protease
SA521422311B1 (ar) صور بلورية لمثبط مستقبل المنشط من البروتياز-4
EA202190689A1 (ru) Производные хинолина в качестве ингибиторов интегрина альфа4бета7